Journal Watch · Proceedings of the National Academy of Sciences (PNAS) · 2026
Cannabinoid tolerance relies on CB<sub>1</sub> receptor ubiquitination by NEDD4L.
These findings reveal a molecular mechanism that controls CB<sub>1</sub>R stability and identify NEDD4L-mediated ubiquitination as a central driver of cannabinoid tolerance.
TL;DR
These findings reveal a molecular mechanism that controls CB<sub>1</sub>R stability and identify NEDD4L-mediated ubiquitination as a central driver of cannabinoid tolerance.
Key findings
- Using molecular, pharmacological, and circuit-specific rescue approaches, we demonstrate that preventing CB<sub>1</sub>R ubiquitination stabilizes receptor levels and abolishes behavioral cannabinoid tolerance in mice without impairing acute drug responses.
- These findings reveal a molecular mechanism that controls CB<sub>1</sub>R stability and identify NEDD4L-mediated ubiquitination as a central driver of cannabinoid tolerance.
What they did
Here, we identify a ubiquitin-dependent pathway that couples CB<sub>1</sub>R activation to its proteasomal degradation. We show that cannabinoids engage a G<sub>q/11</sub>-PLC-PKC signaling cascade that phosphorylates and activates the E3 ubiquitin ligase neural precursor cell-expressed developmentally downregulated 4-like (NEDD4L), promoting its recruitment to CB<sub>1</sub>R and the ubiquitination of four specific lysine residues. This modification targets the receptor for proteasomal clearance, reducing neuronal CB<sub>1</sub>R abundance in vitro and in the mouse brain.
Full abstract (original)
Background: Cannabinoids, the active components of cannabis, exert numerous acute effects in the brain by engaging cannabinoid CB<sub>1</sub> receptors (CB<sub>1</sub>Rs). However, tolerance emerges rapidly after repeated drug exposure, undermining the efficacy of cannabinoid-based therapies and contributing to cannabis-associated adverse effects. Although the processes of CB<sub>1</sub>R short-term desensitization (i.e., receptor uncoupling and internalization) are well characterized, the mechanisms underlying CB<sub>1</sub>R long-term tolerance (i.e., downregulation of receptor protein levels) remain elusive.
What they did: Here, we identify a ubiquitin-dependent pathway that couples CB<sub>1</sub>R activation to its proteasomal degradation. We show that cannabinoids engage a G<sub>q/11</sub>-PLC-PKC signaling cascade that phosphorylates and activates the E3 ubiquitin ligase neural precursor cell-expressed developmentally downregulated 4-like (NEDD4L), promoting its recruitment to CB<sub>1</sub>R and the ubiquitination of four specific lysine residues. This modification targets the receptor for proteasomal clearance, reducing neuronal CB<sub>1</sub>R abundance in vitro and in the mouse brain.
Results & conclusions: Using molecular, pharmacological, and circuit-specific rescue approaches, we demonstrate that preventing CB<sub>1</sub>R ubiquitination stabilizes receptor levels and abolishes behavioral cannabinoid tolerance in mice without impairing acute drug responses. These findings reveal a molecular mechanism that controls CB<sub>1</sub>R stability and identify NEDD4L-mediated ubiquitination as a central driver of cannabinoid tolerance.
Abstract © the authors / Proceedings of the National Academy of Sciences (PNAS) (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1073/pnas.2606671123 · PubMed 42640804.
Why it matters for pharma & biotech
- Relevant to General & Medicine teams tracking Proceedings of the National Academy of Sciences (PNAS) for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Proceedings of the National Academy of Sciences (PNAS) study find?
These findings reveal a molecular mechanism that controls CB<sub>1</sub>R stability and identify NEDD4L-mediated ubiquitination as a central driver of cannabinoid tolerance.
What type of study is this?
It is a preclinical (animal / model) study, published in Proceedings of the National Academy of Sciences (PNAS) in 2026. Here, we identify a ubiquitin-dependent pathway that couples CB<sub>1</sub>R activation to its proteasomal degradation.
Where can I read the original paper?
The original is at the publisher via DOI 10.1073/pnas.2606671123. PubMed ID: 42640804. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cannabinoid-tolerance-relies-on-cb-lt-sub-gt-1-lt-sub-gt-receptor-ubiqui-671123/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides